Tarsus Pharmaceuticals, Inc.
TARSNext catalyst
TP-05 (lotilaner) Low Dose
Lyme Disease
Get an email about TARS's next catalysts
Track Tarsus Pharmaceuticals (TARS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 1 past
TARS Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-1.43 | FQ end Sep/2026 | Call: tbd
TP-05 (lotilaner) Low Dose Phase 2 Est. Readout
Primary completion for TP-05 (lotilaner) Low Dose trial (NCT07562087) in Lyme Disease
SourceMarket Overview
Stock performance and key metrics
TP-03
Meibomian Gland Dysfunction
Low Dose TP-05
Healthy Volunteer
TP-05 (lotilaner) Low Dose
Lyme Disease
Lotilaner
Papulopustular Rosacea
TP-05 (lotilaner) High Dose
Lyme Disease
TP-06
Persistent Corneal Epithelial Defect
High Dose TP-05
Healthy Volunteer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TP-03 | Phase 3 | Meibomian Gland Dysfunction | - | - |
Low Dose TP-05 | Phase 2 | Healthy Volunteer | - | - |
TP-05 (lotilaner) Low Dose | Phase 2 | Lyme Disease | - | - |
Lotilaner | Phase 2 | Papulopustular Rosacea | - | - |
TP-05 (lotilaner) High Dose | Phase 2 | Lyme Disease | - | - |
TP-06 | Phase 2 | Persistent Corneal Epithelial Defect | - | - |
High Dose TP-05 | Phase 2 | Healthy Volunteer | - | - |
Blepharitis
2 drugs in this indication
Meibomian Gland Dysfunction
2 drugs in this indication
Papulopustular Rosacea
2 drugs in this indication
Healthy Volunteer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Tarsus Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Tarsus Pharmaceuticals, Inc.'s (TARS) pipeline across Phase 3, Phase 2. Its lead program is TP-03 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Tarsus Pharmaceuticals, Inc.'s next FDA catalyst?→
Tarsus Pharmaceuticals, Inc.'s (TARS) next tracked catalyst is a Phase 2 readout expected October 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TARS biotech catalysts?→
Add TARS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Tarsus Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.